Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Study Summary

This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.

Conditions

Breast Neoplasms Breast Cancer HER2-positive Early Breast Cancer

Interventions / Drugs

Trastuzumab Deruxtecan Paclitaxel Trastuzumab Pertuzumab Doxorubicin cyclophosphamide

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment927 participants

Primary Completion—

Lead SponsorAstraZeneca

Data Retrieved2026-04-11 02:55:19.910121+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.